Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why MannKind Corporation Stock Is Popping Today


Shares of MannKind Corporation (NASDAQ: MNKD) are rising sharply on Wednesday thanks to bullish commentary from a Wall Street analyst. As of 2:37 p.m. EST, the biopharmaceutical company's shares were up by 10.8%, after rising by as much as 18.4% earlier in the day.

BTIG analyst Robert Hazlett doubled his price target for MannKind to $8, up from $4. The analyst also kept a buy rating on the stock. As of this writing, the company's shares are changing hands for $5.84 apiece, meaning Hazlett's price target still represents a juicy premium over MannKind Corporation's current levels. Why is the analyst so bullish on this small-cap biopharmaceutical company? One of the main reasons behind Hazlett's enthusiasm is MannKind's Treprostinil Technosphere (also know as Tyvaso DPI), a potential treatment for idiopathic pulmonary fibrosis that the company is developing in collaboration with United Therapeutics.

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments